Clinical Trials | July 27, 2022
Nuance Pharma announces the completion of dosing for all NTM-001 Phase 1 clinical study
The NTM-001 Phase I clinical study is expected to be completed by the end of 2022
The NTM-001 Phase I clinical study is expected to be completed by the end of 2022
Tanner will be the supplier of olverembatinib to healthcare providers on a named patient basis in countries where the drug is not commercially available.
72.5% elderly feel their generation used to spend more time with their elders, 52.4% feel lonely, shows PAN Health’s Liberty in Life of Older People 2022 survey
The Award reinforces Cadila’s digital initiatives which is backed by innovation, research & development and robust frameworks.
The region's digital health market, valued at USD 40.3 billion in 2021, is expected to expand to USD 326.7 billion by 2030 at a CAGR of 26.5 per cent.
Sun Pharma will receive from Cassiopea the exclusive right to develop and commercialize WINLEVI in Japan, Australia, New Zealand, Brazil, Mexico and Russia.
Dr. Mona frequently treats children experiencing localized reactions from insect bites and stings.
Better serving global partners and advancing healthcare innovation
Allegra-D had U.S. retail sales of approximately $45 million as of May 2022 according to IRI.
The Elecsys Amyloid Plasma Panel has the potential to ensure better identification of patients that require further confirmatory testing, supporting a more timely and accessible diagnosis.
Subscribe To Our Newsletter & Stay Updated
